First customer boards Recipharm’s soft mist inhaler technology platform
Resyca, Recipharm’s joint venture with Medspray, has boarded its first pharmaceutical customer on the soft mist inhaler (SMI) platform. An agreement has been signed involving milestones and royalties for exclusivity on the specific drug product.
The innovative SMI platform consists of a portable disposable nebuliser featuring a microspray nozzle developed by spray specialist Medspray, which is designed to generate a near-monodisperse aerosol with a high lung dose. The SMI device is purely mechanical, allowing simple aqueous solutions to be used without the need for any propellants. As a result, it can substantially simplify the formulation development process for new inhalation products.
The device platform consists of both prefilled syringe inhaler (PFSI) devices and clinical devices that can be filled on the spot, speeding up clinical investigations. Development, manufacture, filling, assembly and packaging take place within Recipharm Group.
Speaking about the project, Resyca’s Wilbur de Kruijf explained: “The SMI platform has been designed specially to deliver a true turn-key device solution to the customer that requires minimal customisation and simplifies the formulation process. As a result, we can minimise device and drug development timeframes in collaboration with Recipharm, allowing our customers to focus on clinical research.”
Jean-Francois Hilaire, Executive Vice President, Strategy & Global Integration, email@example.com, +33 695 447 507
Wilbur de Kruijf, General Manager, firstname.lastname@example.org
For media enquiries, please contact Lindsay Baldry at ramarketing: email@example.com, +44 779 207 8857, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm and our services, please visit www.recipharm.com
About Resyca device platform
Resyca is a joint venture between Recipharm and Medspray. It was founded at the start of 2021. Resyca is Recipharm’s soft mist inhalation development center, organising everything for the pharma clients as a single hub, from formulation development to analytical testing, to device manufacturing, filling, final assembly, labeling and packaging.